COVID-19 Face Masks and Face Masks Manufacturing Plants Market 2020-2024
|出版商||Homeland Security Research Corporation (HSRC)||商品編碼||950716|
|出版日期||內容資訊||英文 150 Pages; 120 Tables & Figures
|兼容COVID-19的口罩和製造工廠的全球市場：2020-2024 COVID-19 Face Masks and Face Masks Manufacturing Plants Market 2020-2024|
|出版日期: 2020年07月24日||內容資訊: 英文 150 Pages; 120 Tables & Figures||
It is now widely agreed upon that an essential remedy to the suppression of the pandemic is the use of Personal Protective Equipment (PPE). The ability to curb the spread of the pandemic and minimize new surges so that the economy will recover, largely depends on how well the healthcare community and governments will educate their citizens to use Personal Protection Gear, especially face masks.
Currently, China manufactures the majority of the globe's PPE. During Q1 2020, as the coronavirus tore through China and it went into lockdown, Chinese PPE factories ramped up their production. As China started to re-open its economy as the pandemic continued spreading throughout the rest of the world, demand for Personal Protection Gear soared to the point that factory owners in the industry began boasting that they owned money printing machines. As orders of consumer goods shrunk, anxious manufacturers, who had the clean rooms and know-how needed to make PPE, switched their production lines over to make face masks, gloves and PPE gowns.
With demand exploding, full payment up front became the norm. Fraud and counterfeit products proliferated. In April 2020, the PRC government rolled out actions intended to clamp down on counterfeit PPE, and it became even trickier to ship products out of China. For many Chinese tech companies, swooping in as the savior is shrewd publicity. "They have the funds and the political clout, and it's good for their business mission," says J. Norwell Coquillard, executive director of the Washington State China Relations Council, a Seattle-based lobbying group helping local health-care buyers vet Chinese suppliers of PPE.
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen detection, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios: